Reutericyclin

Reutericyclin (Reutericycline) is an orally effective antibacterial and anti-obesity agent that selectively inhibits Gram-positive bacteria. By selectively dissipating transmembrane potential, Reutericyclin exerts non-lytic bactericidal or bacteriostatic activity against pathogens such as Clostridium difficile and Staphylococcus aureus, and rapidly kills vegetative cells and spores of Clostridium difficile. Reutericyclin possesses favorable properties including resistance to enzymatic hydrolysis, iron-chelating function, and poor absorption by colonic epithelium. Reutericyclin not only eradicates staphylococcal biofilms and inhibits drug-resistant strains, but also counteracts Risperidone (HY-11018)-induced weight gain by inducing changes in gut microbiota composition and restoring energy utilization efficiency. Reutericyclin can be used in research related to Clostridium difficile infection, Risperidone-induced weight gain, and staphylococcal superficial skin infections^[1][2][3][4]. In Vitro:The MIC values of Reutericyclin for inhibiting and killing Clostridioides difficile strains 9689, BAA-1803 and BAA-1875 in logarithmic growth phase range from 0.09 to 0.19 mg/L, while its MBC values for the bacteria in stationary phase range from 0.19 to 0.5 mg/L^[1].
Reutericyclin (200 mg/L) exhibits no cytotoxicity against Caco-2 colon cancer cells^[1].
Reutericyclin (0.1-1.6 μg/mL) inhibits the growth of Methicillin (HY-121544)-susceptible and Methicillin-resistant clinical isolates of Staphylococcus aureus, with MIC₅₀ values of 0.8 μg/mL and 3.12 μg/mL, and MIC₉₀ values of 1.6 μg/mL and 6.25 μg/mL, respectively^[3].
Reutericyclin (0.8-3.12 μg/mL) inhibits the growth of mupirocin (HY-B0958)-resistant clinical isolates of Staphylococcus aureus, with an MIC₅₀ of 1.6 μg/mL and an MIC₉₀ of 3.12 μg/mL^[3].
Reutericyclin (0.012-0.4 μg/mL) inhibits the growth of clinical isolates of Streptococcus pyogenes, with an MIC₅₀ of 0.4 μg/mL and an MIC₉₀ of 0.4 μg/mL^[3].
Reutericyclin shows no activity against *Staphylococcus aureus* in an environment containing 50% human serum, with an MIC of ≥200 μg/mL^[3].
Reutericyclin (6.4 mg/L; 60 min; 600 MPa; 90 °C) induces a tailing effect during the inactivation of spores of Clostridium perfringens ATCC 7955 and Clostridium beijerinckii ATCC 8260, but shows no effect on spores of Bacillus amyloliquefaciens FAD 11/2^[4]. In Vivo:Reutericyclin (2.5 μg per day; oral gavage; daily; 25 days) significantly mitigates Risperidone (HY-11018)-induced weight gain in female C57BL/6J mice, reducing average weight gain from 3.58 g to 2.5 g relative to risperidone-only treatment^[2].
Reutericyclin (2.5 μg per day; oral gavage; daily; 50 days) restores energy efficiency and significantly reduces risperidone-induced weight gain in female C57BL/6J mice, even when co-administered with a reutericyclin-deficient L. reuteri mutant^[2].
(R)-reutericyclin (2.5 μg per day; oral gavage; daily) mitigates risperidone-induced weight gain in female C57BL/6J mice, with efficacy lower than that of (S)-reutericyclin^[2].